Innovative retatrutide, a combined-action treatment targeting simultaneously GLP-1 and GIP receptors, is generating considerable interest within the medical community. Initial clinical research have demonstrated impressive losses in physical mass and gains in physiological markers for people with overweight. Scientists believe this novel approach